The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 74 of the 148 sources its claims cite were checked for support.
Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor
Open accessAbstract
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease marked by cholestasis and progressive fibrosis. While ursodeoxycholic acid (UDCA) remains the first-line therapy, approximately 30-40% of patients have an inadequate biochemical response, increasing the risk of disease progression. Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, was the first second-line agent approved by the only Food and Drug Administration (FDA) and has demonstrated moderate biochemical efficacy but limited tolerability due to dose-dependent pruritus and safety concerns in cirrhosis. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, showed substantial alkaline phosphatase (ALP) reductions when added to UDCA, although its long-term benefit remains unconfirmed in large-scale trials and its use remains off-label in the United States, unlike FDA-approved agents. Seladelpar, a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, and elafibranor, a dual PPAR-α/δ agonist, have both recently received FDA accelerated approval after demonstrating significant improvements in ALP, biochemical response rates, and pruritus relief in phase 3 trials. This review summarizes these second-line therapies' mechanisms, efficacy, safety, and limitations emphasizing the need for individualized treatment decisions and ongoing research into long-term clinical outcomes.
Overview
CoChat Summary
TL;DR
This comparative review summarizes mechanisms, efficacy, safety, and limitations of second-line therapies for primary biliary cholangitis: obeticholic acid, fibrates, seladelpar, and elafibranor. It concludes that all improve biochemical endpoints, but long-term outcome data remain limited and treatment should be individualized.
Key findings
- Obeticholic acid (OCA): In POISE, the primary endpoint was achieved by 46% of the 5–10 mg group and 47% of the 10 mg group vs 10% with placebo (p < 0.001). In an observational study of 191 patients, median reductions at 12 months were ALP −32.3%, ALT −31.4%, and bilirubin −11.2%; cirrhosis was associated with lower response (29.5% vs 49.2%; p = 0.01) and higher discontinuation (30% vs 12%; p = 0.004). Safety concerns include dose-dependent pruritus and a 3.9-fold increased risk of hepatic decompensation in PBC-related cirrhosis; annual cost was approximately $69,000, with an ICER of $473,400 per QALY.
- Fibrates: In BEZURSO, 24-month biochemical response occurred in 31% with bezafibrate vs 0% with placebo (p < 0.001), and ALP normalization in 67% vs 2% (p < 0.001). A randomized trial of fenofibrate plus UDCA reported Barcelona response in 81.4% vs 64.3% with UDCA alone (p = 0.048). Fibrates remain off-label for PBC in the United States; adverse events included myalgia (20% vs 10%) and reversible creatinine elevation.
- Seladelpar: In ENHANCE at 3 months, composite biochemical response was 78.2% with 10 mg and 57.1% with 5 mg vs 12.5% with placebo (p < 0.0001); ALP < 1.67 × ULN occurred in 95% and 95% vs 23% (p < 0.0001). In RESPONSE, composite response was 61.7% vs 20.0% (p < 0.001), ALP normalization 25% vs 0% (p < 0.001), and pruritus NRS change −3.2 vs −1.7 (p = 0.005). ASSURE reported sustained composite response in 72% and new response in 94% of crossover patients at 12 months.
- Elafibranor: In a phase 2 trial, ALP decreased by −48.3% with 80 mg and −40.6% with 120 mg vs +3.2% with placebo (p < 0.001 for both); composite endpoint was achieved by 67% and 79% vs 6.7%. In ELATIVE, biochemical response occurred in 51% vs 4% with placebo (p < 0.001), ALP normalization in 15% vs 0% (p < 0.002), and WI-NRS change did not differ significantly between groups. It received FDA accelerated approval in 2024.
Methods
- Narrative comparative review; no systematic review methods, search strategy, or formal risk-of-bias assessment are described.
- Synthesizes published clinical trials, observational studies, and guidelines for OCA, fibrates, seladelpar, and elafibranor, including POISE, D’Amato, Gomez, BEZURSO, fenofibrate trials, ENHANCE, RESPONSE, ASSURE, elafibranor phase 2, and ELATIVE.
- Main analysis is qualitative comparison of mechanisms, biochemical efficacy, pruritus effects, safety, and regulatory status; no meta-analysis or pooled statistics are reported.
Limitations
- The paper states that the evidence base is largely driven by surrogate biochemical endpoints, with limited long-term data on fibrosis progression, transplantation, or survival, constraining firm treatment algorithms.
- The paper notes that trials excluded patients with decompensated cirrhosis or advanced liver failure and autoimmune overlap syndromes, limiting generalizability; ELATIVE enrolled mostly white patients, with racial minorities underrepresented and ethnicity data not recorded.
- Evident from the text: as a narrative review without a described systematic search or formal quality assessment, selection and synthesis may be subject to bias.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
64 Valid · 1 Not valid · 56 Not checked · 14 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The proportion of patients who achieved ALP < 1.67 × ULN at 3 months was higher in the 10 mg seladelpar group (95%) and the 5 mg seladelpar group (95%), compared to placebo (23%) (p < 0.0001 in both comparisons).”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 4. Seladelpar > 4.2. Clinical Trials & Efficacy
What the sources say
- Disputedcites [16] Hirschfield, 2023, Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study, Hepatology sourceExperimental — accuracy not yet measured
The Results > Efficacy passage reports that 18% of placebo patients, 64% of the 5-mg group, and 82% of the 10-mg group achieved ALP <1.67×ULN at month 3. The claimed 23%, 95%, and 95% are instead the percentages who achieved a ≥15% decrease in ALP from baseline. The cited passage does not give p-values for the individual ALP <1.67×ULN comparison. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Elafibranor functions as an agonist of PPAR-α/δ [49].”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 5. Elafibranor > 5.1. Mechanism of Action
What the sources say
- Supportedcites [49] Ratziu, 2016, Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening, Gastroenterology source
The introductory passage (p. 2) explicitly describes elafibranor as a dual PPAR-α/δ agonist. The opening summary (p. 1) also identifies it as an agonist of both receptors. (LLM, conf=0.95)
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Changes in transient elastography and enhanced liver fibrosis (ELF) scores from baseline to 12 months were not significantly different between treatment groups (p = 0.6818 and p = 0.4718 for 5–10 mg OCA vs. placebo; p = 0.3267 and p = 0.2324 for 10 mg OCA vs. placebo, respectively [27].”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 2. Obeticholic Acid > 2.2. Clinical Trials & Efficacy
What the sources say
- Partly supportedcites [27] Nevens, 2016, A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Secondary End Points section (p. 7) states that changes from baseline to 12 months in transient elastography and enhanced liver fibrosis scores did not differ significantly between either obeticholic acid group and placebo. Our copy does not give the four exact P values in the citing sentence, so those figures cannot be verified from it. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients with PBC- autoimmune hepatitis (AIH) overlap had comparable response rates to those with PBC alone (46.4% vs. 42.3%; p = 0.68) but experienced greater reductions in ALT at 6 months (−38% vs. −29%; p = 0.04).”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 2. Obeticholic Acid > 2.2. Clinical Trials & Efficacy
What the sources say
- Supportedcites [28] Malinverno, 2021, Real-world experience with obeticholic acid in patients with primary biliary cholangitis, JHEP Rep. source
The Abstract Results report that patients with PBC-AIH overlap had a similar response to those with pure PBC (46.4% vs. 42.3%; p = 0.68). The Results section on treatment response in PBC-AIH overlap patients also reports no difference in response rates at 6 or 12 months. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“According to the American Association for the Study of Liver Diseases (AASLD), ursodeoxycholic acid (UDCA) is the first-line treatment for PBC [7].”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 1. Introduction
What the sources say
- Supportedcites [7] Lindor, 2019, Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases, Hepatology source
The guidance’s “Therapy for PBC—UDCA” section explicitly calls UDCA at 13–15 mg/kg/day the first-line therapy for PBC. Its Guidance statements also recommend UDCA for patients with abnormal liver enzyme values, regardless of histologic stage. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
80 more claims · 34 with their cited sources checked
Create a free account to see all 135 claims and to verify the 6 references still open.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“36/60 patients (64.3%) in the UDCA-only group”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 3. Peroxisome Proliferator-Activated Receptor-Alpha Agonists > 3.2. Clinical Trials & Efficacy
Reported 64.3 · recomputed 60
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > Abstract
“Seladelpar, a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, and elafibranor, a dual PPAR-α/δ agonist, have both recently received FDA accelerated approval after demonstrating significant improvements in ALP, biochemical response rates, and pruritus relief in phase 3 trials.”
§ Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor > 5. Elafibranor > 5.2. Clinical Trials & Efficacy
“Among patients with moderate-to-severe pruritus (44 in the elafibranor group and 22 in the placebo group), the least-squares mean change in WI-NRS score from baseline through week 52 did not differ significantly between the two groups.”
Citations
Cites
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 7×
“From a comparative perspective, OCA and fibrates both achieve ALP reduction, but fibrates often provide greater biochemical response and potential pruritus relief, whereas OCA is limited by dose-dependent pruritus and contraindications in cirrhosis [15,22,27].”
InfluentialRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035 · cited 2×
“Elafibranor functions as an agonist of PPAR-α / δ [49].”
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 9×
“Currently, fibrates are only approved by the FDA as lipid-lowering medications in the United States (US) and multiple countries rather than PBC treatment [7].”
InfluentialA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2306185 · Cited by 314
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308 · cited 1×
“Primary Biliary Cholangitis (PBC) is a common autoimmune liver disease, with a global prevalence ranging from 1.9 to 40.2 cases per 100,000 and incidence estimates be-tween 0.3 and 5.8 per 100,000 per year, depending on geography [1,2].”
InfluentialA Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286 · cited 4×
“However, ALT and GGT were significantly decreased with seladelpar which indicates reduced hepatocellular injury [47].”
Influential
Cited by
Programmed cell death in acute kidney injury: From molecular mechanisms to targeted therapies
Xu, B., Zheng, Y., Hu, Y., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118860 · Cited by 1
Cholestatic Immune-Mediated Diseases Management – Part 2
Mandea, M., & Gheorghe, L. S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016073
Bokhari, B. T., Saleh, A. M., Aljohani, H. M., Owaydhah, W. H., Alobaidy, M. A., Dahran, N. A., Naffadi, H. M., & Eisa, A. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343274 · Cited by 1
Romeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 2
Cholestatic Immune-Mediated Diseases Management – Part 1
Mandea, M., & Gheorghe, L. S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016072
Metadata
- Authors
- Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., Malik, T. A., & Lizaola-Mayo, B. C.
- Affiliations
- Mayo Clinic (US)
- Department of Cardiology, Mayo Clinic, Phoenix, AZ 85054, USA
- Department of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85054, USA
- Corresponding author
- Jamal, Fares
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2025-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 2335
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC12561627
- OpenAlex
- W4414517587
- Semantic Scholar
- 4b198bce7794caafafe41b6a4b7031dc3bc960c4
- Cited by
- 6
- References
- 46
- Citations by year
- 2026: 6
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary biliary cirrhosis, second-line therapy, obeticholic acid, fibrates, fenofibrate, seladelpar, elafibranor, farnesoid X receptor agonist, PPARα agonist, PPARδ agonist, ursodeoxycholic acid, cholestasis, pruritus, alkaline phosphatase, liver fibrosis, drug safety and tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. https://app.cochat.ai/papers/10.3390/biomedicines13102335
- The paper
- Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., Malik, T. A., & Lizaola-Mayo, B. C. (2025). Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. Biomedicines. https://doi.org/10.3390/biomedicines13102335
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
